Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Minoru Takada"'
Autor:
Kenji Tezuka, Kosei Hirakawa, Shigehito Yamagata, Mao Tokumoto, Minoru Takada, Takeo Nishimori, Katsumi Ikeda, Shinya Tokunaga, Hidemi Kawajiri, Yoshinari Ogawa, Yoko Mizuyama, Takeshi Sunami, Tsutomu Takashima, Shinichiro Kashiwagi, Masaichi Ohira, Tetsuro Ishikawa, Shinzoh Kudoh, Satoru Noda, Shigehiko Nishimura
Publikováno v:
Anticancer Research. 39:2053-2059
Aim This study was conducted in order to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus trastuzumab followed by 5-fluorouracil/ epirubicin/cyclophosphamide (FEC) in a neoadjuvant chemotherapy (NAC) set
Autor:
Shigehiko Nishimura, Takeo Nishimori, Shigehito Yamagata, Naoyoshi Onoda, Kosei Hirakawa, Tsutomu Takashima, Shinya Tokunaga, Hidemi Kawajiri, Katsumi Ikeda, Satoru Noda, Seika Tei, Kenji Tezuka, Shinichiro Kashiwagi, Yoko Mizuyama, Yoshinari Ogawa, Takeshi Sunami, Minoru Takada, Tetsuro Ishikawa, Shinzoh Kudoh
Publikováno v:
Molecular and Clinical Oncology. 6:534-538
Although the concurrent use of anthracycline-containing chemotherapy and taxane with trastuzumab are considered the treatment of choice for the primary systemic therapy of human epidermal growth factor receptor 2 (HER2)-overexpressing early breast ca
Autor:
Kosei Hirakawa, Shinzoh Kudoh, Minoru Takada, Satoru Noda, Naoyoshi Onoda, Yoshinari Ogawa, Takeo Nishimori, Hidemi Kawajiri, Katsumi Ikeda, Tetsuro Ishikawa, Yoko Mizuyama, Tsutomu Takashima, Masaichi Ohira, Shigehito Yamagata, Seika Tei, Shinya Tokunaga, Kenji Tezuka, Shinichiro Kashiwagi, Takeshi Sunami, Shigehiko Nishimura
Publikováno v:
European Journal of Cancer. 138:S62
Background/aim In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC) patients. Patients and meth
Autor:
Takeshi Sunami, Kosei Hirakawa, Yoshinari Ogawa, Katsumi Ikeda, Minoru Takada, Kenji Tezuka, Shigehiko Nishimura, Shigehito Yamagata, Naoyoshi Onoda, Masaichi Ohira, Hidemi Kawajiri, Seika Tei, Shinzoh Kudoh, Takeo Nishimori, Yoko Mizuyama, Shinichiro Kashiwagi, Shinya Tokunaga, Tsutomu Takashima, Tetsuro Ishikawa, Satoru Noda
Publikováno v:
Anticancer research. 38(1)
Background/aim Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel formulation. Although nab-PTX has shown superior efficacy compared to conventional paclitaxel (PTX) in metastatic breast cancer (MBC), chemotherapy-induced peripheral neuropathy (
Autor:
Akihito Kubo, Yoko Kusunoki, Kazuhiro Asami, Minoru Takada, Masahiko Ando, Shojiro Minomo, Shinji Atagi, Yoji Ogawa, Kazutaka Uehira, Yoshinobu Matsuda, Kaoru Maruyama, Mari Ishii, Tomoya Kawaguchi, Masaki Kanazu
Publikováno v:
Clinical Lung Cancer. 15:182-187
Early prediction of therapeutic outcome is important in determining whether the ongoing therapy is beneficial. In addition to anatomical response determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, recent studies have
Autor:
Shinichiro Kashiwagi, Yoshinari Ogawa, Shinya Tokunaga, Shinzoh Kudoh, Katsumi Ikeda, Satoru Noda, Yoko Mizuyama, Shigehito Yamagata, Takeo Nishimori, Tsutomu Takashima, Naoyoshi Onoda, Hidemi Kawajiri, Kenji Tezuka, Takeshi Sunami, Seika Tei, Minoru Takada, Shigehiko Nishimura, Tetsuro Ishikawa, Kosei Hirakawa
Publikováno v:
SpringerPlus
The treatment goals for metastatic breast cancer (MBC) are prolonging survival and improving the quality of life. Eribulin, a non-taxane tubulin inhibitor, demonstrated improved survival in previous studies and also showed mild toxicity when used in
Autor:
Akihito Kubo, Taisuke Tsuji, Yoshikazu Hasegawa, Kazuhiko Nakagawa, Masahiko Ando, Kazuyuki Tsujino, Shun Ichi Isa, Tomoya Kawaguchi, Sai-Hong Ignatius Ou, Junji Shiraishi, Minoru Takada
Publikováno v:
Journal of Thoracic Oncology. 6:1881-1888
IntroductionThere are a large number of global clinical trials ongoing for patients with non-small cell lung cancer (NSCLC). Ethnic difference in toxicity has not been adequately studied.MethodsWe performed a systematic search in PubMed for randomize
Autor:
Kazuhiko Nakagawa, Hisao Uejima, Tatsuhiko Kashii, Minoru Takada, Kaoru Matsui, Y. Takada, Nobuyuki Yamamoto, Yoichi Nakanishi, Takahiko Sugiura, Terufumi Kato, Shun Ichi Negoro, Masahiro Fukuoka
Publikováno v:
Cancer. 107:599-605
BACKGROUND. Combined gemcitabine and carboplatin (GC) and combined gemcitabine and vinorelbine (GV) are active and well tolerated chemotherapeutic regimens for patients with advanced nonsmall cell lung cancer (NSCLC). The authors conducted a randomiz
Autor:
Akihito Kubo, Tomoya Kawaguchi, Kyoichi Okishio, Shun-ichi Isa, Minoru Takada, Masanori Kitaichi, Akihiro Tamiya, Kazuhiro Asami, Akihide Matsumura, Shigeki Shimizu, Shinji Atagi
Publikováno v:
Internal medicine (Tokyo, Japan). 53(22)
A 47-year-old man was referred to our department due to multiple metastases in the lungs and liver with pleural dissemination six weeks after undergoing curative surgery for lung pleomorphic carcinoma. He received two regimens of chemotherapy, both o
Autor:
Naoya Okada, Nobuichi Kashimura, Toru Nakamura, Minoru Takada, Yoshiyasu Ambo, Fumitaka Nakamura, Akihiro Kishida
Publikováno v:
Surgical infections. 15(3)
Surgical site infection (SSI) is a serious complication after pancreaticoduodenectomy (PD). To prevent microbial colonization of suture material in operative wounds, triclosan-coated polyglactin sutures with antibacterial activity have been developed